Skip to main content
Kolinpharma logo

Kolinpharma — Investor Relations & Filings

Ticker · KIP ISIN · IT0005322950 LEI · 815600FC8F1A3BED2743 XMIL Manufacturing
Open in API
Filings indexed 222 across all filing types
Latest filing 2020-04-29 AGM Information
Country IT Italy
Listing XMIL KIP

About Kolinpharma

https://www.kolinpharma.com/index-en

Kolinpharma is a nutraceutical company established in 2013, specializing in the research and development of innovative products designed to improve well-being and quality of life. The company's core activities are centered on scientific research and product innovation, creating high-quality nutraceuticals. It operates an in-house R&D department and collaborates with leading universities for in-vitro and clinical studies. As a certified B Corporation, Kolinpharma adheres to high standards of social and environmental performance. The company distributes its proprietary branded products through a qualified network of medical-scientific representatives.

Recent filings

Filing Released Lang Actions
KOLINPHARMA-L'ASSEMBLEA APPROVA IL BILANCIO 2019 E RINNOVA LA GOVERNANCE-PRESENTATO 1° BILANCIO DI SOSTENIBILITA'
AGM Information Classification · 1% confidence The document is a formal communication from KOLINPHARMA S.p.A. dated April 29, 2020, detailing the outcomes of its Shareholders' Meeting (Assemblea). The key topics covered are the approval of the 2019 Financial Statements (Bilancio 2019), the presentation of the first Voluntary Sustainability Report (Bilancio di Sostenibilità), and the renewal/appointment of the Board of Directors (Consiglio di Amministrazione) and Statutory Auditors (Collegio Sindacale). The approval of the annual financial statements and the related governance changes (Board/Auditors) strongly suggest this is related to the Annual General Meeting (AGM). Since the document explicitly details the results of the shareholder vote on these items and the meeting itself, the most appropriate classification is AGM Information (AGM-R). While it mentions the approval of the 2019 Financial Statements, the primary context is the meeting where these approvals occurred, not the full 10-K report itself. It is not a simple Earnings Release (ER) as it covers governance and sustainability in depth, nor is it just a DVA (Declaration of Voting Results) as it contains substantive information about the approved reports and governance structure.
2020-04-29 Italian
comunicato internal dealing
Director's Dealing Classification · 1% confidence The document header explicitly states the 'Oggetto' (Subject) is 'comunicato internal dealing' (internal dealing communication). Furthermore, the template used is titled 'Template for notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.' This directly corresponds to the definition of Director's Dealing (insider trades) which is classified under the code DIRS.
2020-04-24 Italian
Comunicazione variazione partecipazione rilevante
Major Shareholding Notification Classification · 1% confidence The document is an official communication from KOLINPHARMA S.p.A. regarding a 'Comunicazione variazione partecipazione rilevante' (Communication of relevant shareholding change). It details the transfer of a significant block of shares by the controlling shareholder, resulting in a change in ownership percentage (from 71.82% to 59.62%) and an increase in the free float. This type of disclosure, which reports changes in significant share ownership levels crossing thresholds, directly corresponds to the definition of Major Shareholding Notification (MRQ). Although it involves a transaction, the primary regulatory focus here is the change in ownership structure reported to the market, not just the buyback itself (POS) or a general regulatory filing (RNS).
2020-04-22 Italian
KOLINPHARMA SPA-OTTIENE IL 1° BREVETTO IN ISRAELE PER IL PRODOTTO XINEPA®
Regulatory Filings Classification · 1% confidence The document is an official communication from KOLINPHARMA S.p.A. dated April 16, 2020, identified by the header 'Informazione Regolamentata n. 20125-11-2020' and the 'Oggetto' (Subject) stating: 'KOLINPHARMA SPA-OTTIENE IL 1° BREVETTO IN ISRAELE PER IL PRODOTTO XINEPA®'. The content details the granting of a patent in Israel for the product Xinepa®. This type of announcement, concerning specific corporate news (like patents, legal updates, or significant operational milestones) released via regulatory channels (AIM Italia/Mercato Alternativo del Capitale), fits best under the general category of Regulatory Filings (RNS), as it is not a standard financial report (10-K, IR, ER, MRQ) nor a specific announcement like Director's Dealing (DIRS) or Dividend (DIV). Since it is a specific, non-financial regulatory announcement, RNS is the most appropriate fallback, although it could also be argued as a general Investor Relations communication. Given the structure and the 'Informazione Regolamentata' tag, RNS is chosen over LTR (Legal Proceedings) or IP (Investor Presentation).
2020-04-16 Italian
KOLINPHARMA SPA-Pubblicazione Avviso Convocazione Assemblea Ordinaria e relativa documentazione
AGM Information Classification · 1% confidence The document is an official notice from KOLINPHARMA S.p.A. titled "AVVISO DI CONVOCAZIONE ASSEMBLEA ORDINARIA E PUBBLICAZIONE DELLA RELATIVA DOCUMENTAZIONE" (Notice of Call for Ordinary Shareholders' Meeting and Publication of Related Documentation). It details the date, time, and agenda for an upcoming shareholders' meeting (Assemblea), which includes items like the approval of the 2019 financial statements, appointment of the Board of Directors, and appointment of the Statutory Auditors. This content directly relates to the formal procedures and materials associated with an Annual General Meeting (AGM). Although it mentions the publication of documentation, the primary purpose and content focus on the convocation and agenda for the AGM itself, making AGM-R the most appropriate classification over RPA or RNS.
2020-04-16 Italian
KOLINPHARMA SPA- Il CDA approva con ottimi risultati il progetto di bilancio di esercizio al 31/12/2019
Earnings Release Classification · 1% confidence The document is an official communication from KOLINPHARMA S.p.A. dated April 3, 2020, announcing that the Board of Directors (CDA) approved the draft of the financial statements (progetto di bilancio di esercizio) for the year ended December 31, 2019. It details key financial results (Revenues, EBITDA, Net Income) and provides commentary from the President. This structure—an official announcement of approved annual financial results, including key figures and management commentary, often released before the final filing—is characteristic of an Earnings Release (ER) or a preliminary report announcement. Since it contains comprehensive financial highlights and management discussion, it aligns best with the 'Earnings Release' (ER) definition, which covers the initial announcement of periodical financial results (key highlights only). Although it mentions the 'bilancio di esercizio' (annual statement), the format is a press release announcing the approval, not the full 10-K document itself. Given the detailed financial summary, ER is more appropriate than RPA or RNS. FY 2019
2020-04-03 Italian

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.